Table 4. Impact on baseline laboratory values on survival following RE (any abnormality and beyond current guidelines).
| Parameter | Any abnormal laboratory value (CTCAE >0) | Outside current guidelines | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value* | Hazard ratio (95% CI) | P value* | ||
| Total bilirubin | 2.2 (1.6–3.1) | <0.001 | 3.1 (1.7–5.6) | <0.001 | |
| Albumin | 2.0 (1.6–2.4) | <0.001 | 3.2 (2.5–4.2) | <0.001 | |
| Alk Phos | 2.2 (1.8–2.6) | <0.001 | 2.8 (2.2–3.5)** 6.8 (4.2–11.06) |
<0.001 | |
| ALT | 1.2 (1.0–1.4) | 0.117 | 3.6 (1.1–11.1) | 0.029 | |
| AST C | 1.9 (1.6–2.3) | <0.001 | 5.3 (2.7–10.4) | <0.001 | |
| Creatinine | 1.5 (1.0–2.4) | 0.043 | 6.0 (1.9–18.8) | 0.002 | |
| Hemoglobin <10 g/dL | 1.8 (1.3–2.5) | <0.001 | Not applicable | — | |
*, Cox poroportional hazards model; **, Alk phosph >300 U/L; ***, Alk phosph >630 U/L. CTCAEs, Common Terminology Criteria Adverse Events; CI, ALT, alanine transaminase; AST, aspartate aminotransferase; Alk phosph, alkaline phosphatase.